Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Dipesh Navsaria MPH, MSLIS, MD
Dipesh Navsaria MPH, MSLIS, MD Advisory Board
Chill Yee MD
Chill C. Yee MD Advisory Board
Jonathan Temte MD, PhD
Jonathan Temte MD, PhD Advisory Board
See All Experts
featured
Published in Primary Care

Expert Opinion / My Approach · October 22, 2019

MY APPROACH to Choosing a Direct Oral Anticoagulant (DOAC)

Allison Burnett PharmD, PhC, CACP
Emily Shephard MD

 

 Save  Recommend
 Share

Additional Info

  1. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124:2450-2458.
  2. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2019;140(2):e125-e151.
  3. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease CHEST guideline and Expert Panel report. CHEST. 2016;149(2):315-352.
  4. Kushner M, Choi Y, Eisenberg R, et al. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Lancet Haematol. 2019;6(7):e359-e365.
  5. McBane Ii R, Loprinzi CL, Ashrani A, et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism. Thromb Haemost. 2017;117(10):1952-1961.
  6. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018; 378(7):615-624.
  7. Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013-2014. JAMA. 2016;316(20):2115-2125.
  8. Streiff MB, Holmstrom B, Angelini D, et al. NCCN clinical practice guidelines in oncology. Cancer-associated venous thromboembolic disease, version 1.2019. Published February 28, 2019.
  9. Steinberg BA, Shrader P, Thomas L, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016;68(24):2597-2604.
  10. Trujillo-Santos J, Di Micco P, Dentali F, et al. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. Thromb Haemost. 2017;117(2):382-389.
  11. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;(36)20:2017-2023.

Disclosure statements are available on the authors' profiles:

Allison Burnett PharmD, PhC, CACP

Emily Shephard MD

Further Reading

Most Read This Week

Recently Updated